Squamous cell carcinoma
☆ Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
Squamous cell carcinoma well differentiated ― An adjacent actinic keratosis inoonekwa.
References
Squamous cell carcinoma (SCC) ndiyo yechipiri yakajairika gomarara reganda muUnited States, mushure me basal cell carcinoma. Iyo inowanzotanga kubva kune precancerous maronda anonzi actinic keratosis , uye inogona kupararira kune dzimwe nhengo dzemuviri. Chikonzero chikuru kuratidzwa kwemwaranzi yeultraviolet (UV) kubva kuzuva, iyo inoungana nekufamba kwenguva. Kurapa kunowanzobatanidza kuvhiyiwa kubviswa, kunyanya kune SCC pamusoro uye mutsipa. Radiation therapy isarudzo yevarwere vakura kana avo vasingakwanise kuvhiyiwa. Immunosuppression inowedzera njodzi yeSCC. Kunyangwe zvisingawanzo, SCC inogona kupararira, kunyanya muvarwere vane immune system isina simba. Kugara uchiongororwa uye kudzivirira zuva kwakakosha kune avo vane SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) igomarara rechipiri muvanhu, uye nhamba dzaro dziri kukwira. Kunyange zvazvo CSCC inowanzoratidza maitiro asina kunaka ekliniki, inogona kupararira zvose munharaunda uye kune dzimwe nzvimbo dzomuviri. Masayendisiti akaona nzira dzakananga dzinobatanidzwa mukuvandudza kweCSCC, zvichitungamira kumishonga mitsva. Huwandu hwepamusoro hwekuchinja uye njodzi yakawedzera muvarwere vane immunosuppressed yakakurudzira kuvandudzwa kwe immunotherapy. Ongororo iyi inotarisa ma genetic midzi yeCSCC uye neazvino marapirwo akananga chaiwo mamorekuru uye immune system.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Kuongororwa uye Kurapwa
#Dermoscopy
#Skin biopsy